Skip to content
Companies

Celestial Therapeutics

Broad-spectrum anti-infective drug for RSV

Raised to date

$850K

across 8 Form D filings

Investors
5
Last filed
Jul 6, 2026

About

Celestial Therapeutics Inc. is a biopharmaceutical company dedicated to developing innovative therapies aimed at treating, preventing, and curing infectious diseases, inflammatory conditions, and various forms of cancer. With a strong focus on addressing key unmet medical needs, the company integrates cutting-edge technology into its therapeutic solutions.

Celestial Therapeutics distinguishes itself by leveraging a proprietary self-adjuvanting mRNA vaccine platform that enhances immunogenicity while minimizing side effects.

Funding

  • EquityFiled Jul 6, 2026Form D/A
    $850K/ no target
  • EquityFiled Oct 9, 2025Form D/A
    $800K/ no target
  • EquityFiled Jun 23, 2025Form D/A
    $775K/ no target
  • EquityFiled May 21, 2025Form D/A
    $725K/ no target
  • EquityFiled May 8, 2025Form D/A
    $625K/ no target
  • EquityFiled Apr 25, 2025Form D/A
    $575K/ no target
  • EquityFiled Apr 7, 2025Form D/A
    $550K/ no target
  • EquityFiled Mar 27, 2025Form D/A
    $500K/ no target

Product

CT-02

Therapeutics

CT-02 is a first-in-class broad-spectrum anti-infective and anti-inflammatory drug primarily developed for the treatment of respiratory syncytial virus (RSV). It represents a significant advancement in the realm of infectious disease management by providing effective treatment options for viral infections.

  • Broad-spectrum activity against multiple pathogens
  • Dual action as anti-infective and anti-inflammatory
  • Targeted initially at respiratory viral infections

Built for

Healthcare providers, hospitals, and patients

People on file